Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Asahi Intecc Co ( (JP:7747) ) has provided an update.
Asahi Intecc has signed an exclusive distribution agreement with South Korea’s NEXTBIOMEDICAL to sell the embolization agent Nexsphere-F in Japan, targeting use in Transcatheter Arterial Micro-Embolization procedures for chronic pain. Although the product is not yet approved domestically, Asahi Intecc plans to obtain regulatory approval, secure national health insurance coverage, and distribute it through its subsidiary Asahi Intecc J-sales.
The company aims to capitalize on its existing catheter and guidewire portfolio to create synergies, broaden TAME as a treatment option, and enhance quality of life for chronic pain patients. Nexsphere-F already has overseas clinical use and is sold in Asahi Intecc’s European direct sales regions, suggesting that accumulated clinical evidence may support its introduction and positioning in the Japanese market, with no immediate impact on current-period consolidated earnings.
The most recent analyst rating on (JP:7747) stock is a Hold with a Yen4014.00 price target. To see the full list of analyst forecasts on Asahi Intecc Co stock, see the JP:7747 Stock Forecast page.
More about Asahi Intecc Co
Asahi Intecc Co., Ltd. is a Japanese medical device manufacturer listed on the Prime Market of the Tokyo Stock Exchange and the Premier Market of the Nagoya Stock Exchange. The company focuses on minimally invasive medical technologies, including guidewires and microcatheters, and leverages a direct sales network and strong relationships with physicians in Japan and overseas.
Average Trading Volume: 1,413,694
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen977.2B
Find detailed analytics on 7747 stock on TipRanks’ Stock Analysis page.